Related Experiment Video
Updated: Jul 3, 2026

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
BFEE-Docking: A User-Friendly and Customizable End-to-End Tool from High-Throughput Virtual Screening to Binding
Xiwen Sun1,2, Zihong Li3, Xueguang Shao1,2
1Research Center for Analytical Sciences, Tianjin Key Laboratory of Biosensing and Molecular Recognition, College of Chemistry, Nankai University, Tianjin 300071, China.
None:
Rational drug design typically relies on a sequential workflow comprising virtual screening, flexible redocking, and free energy calculations. Specialized tools exist for individual steps, including our Binding Free-Energy Estimator 3 (BFEE3) for absolute binding free-energy (ABFE) calculations. However, the field lacks an open-source platform that seamlessly connects virtual screening to rigorous free-energy evaluation while allowing nonspecialists to customize intermediate stages. Although commercial suites offer such integration, they often suffer from limited accessibility. To address this limitation, we develop BFEE-docking as a companion platform to BFEE3, extending BFEE3 toward an integrated, automated drug-discovery workflow. Requiring only a standard protein PDB file and a ligand database (SMI/SDF), this cross-platform software automates GPU-accelerated virtual screening, flexible redocking, and free-energy estimation using either MM-GBSA or BFEE3-based ABFE calculations. The software autonomously handles complex preparatory tasks, including pH-based protonation, chain cleaning, binding site identification, and file format conversion. Notably, BFEE-docking interfaces directly with PyMOL to provide real-time visualization of intermediate results, including binding site locations, docked ligand conformations, and flexible residue configurations. This feature allows the end-user, regardless of their computational background, to inspect and customize the protocol on the fly. We demonstrate the usefulness of BFEE-docking through a challenging inhibitor screening campaign against the epidermal growth factor receptor triple mutant (EGFRTM), achieving formally exact binding free-energy evaluation within the screening workflow while preserving protonation-state-specific docking poses for separate MM-GBSA or ABFE calculations. The pipeline successfully identifies two novel potential inhibitors overlooked in our previous studies, showing the reliability and effectiveness of BFEE-docking in drug discovery.
Related Concept Videos
The Equilibrium Binding Constant and Binding Strength
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-Drug Binding: Determination Methods
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
